Co-Founder Axel Bolte Just Bought 36% More Shares In Inozyme Pharma, Inc. (NASDAQ:INZY)
Potential Inozyme Pharma, Inc. (NASDAQ:INZY) shareholders may wish to note that the Co-Founder, Axel Bolte, recently bought US$250k worth of stock, paying US$3.69 for each share. That's a very decent purchase to our minds and it grew their holding by a solid 36%.
See our latest analysis for Inozyme Pharma
The Last 12 Months Of Insider Transactions At Inozyme Pharma
In fact, the recent purchase by Axel Bolte was the biggest purchase of Inozyme Pharma shares made by an insider individual in the last twelve months, according to our records. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$4.14. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.
Inozyme Pharma insiders may have bought shares in the last year, but they didn't sell any. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).
Insider Ownership
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. Based on our data, Inozyme Pharma insiders have about 1.9% of the stock, worth approximately US$3.2m. We consider this fairly low insider ownership.
So What Does This Data Suggest About Inozyme Pharma Insiders?
It is good to see recent purchasing. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Inozyme Pharma insiders are expecting a bright future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Inozyme Pharma. Our analysis shows 5 warning signs for Inozyme Pharma (3 shouldn't be ignored!) and we strongly recommend you look at them before investing.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
